How to Value a Supplement or Nutrition Brand in 2026

The supplement and nutrition industry is one of the most bifurcated markets I work with from a valuation standpoint. I've seen brands with $10M in revenue sell for $50M, and I've seen brands with $10M in revenue struggle to find a buyer at $8M. The difference isn't revenue — it's the composition of that revenue, the channel mix, the brand moat, and whether the business has built a real consumer relationship or is just arbitraging paid media on Amazon.

If you've built a supplement or nutrition brand and you're thinking about an exit, you need to understand exactly what buyers are paying for in this space — because it's not what most founders think.

The Revenue Multiple Spectrum

Supplement brands are valued primarily on revenue multiples, with EBITDA as a secondary lens. The range is wide:

• Commodity/wholesale brands: 1-2x revenue. These are private-label or undifferentiated products sold primarily through wholesale channels, Amazon wholesale, or mass retail. Margins are thin (20-35% gross), brand loyalty is low, and the business is essentially a manufacturing and distribution operation.
• Established DTC brands: 2-4x revenue. These have a recognizable brand, direct customer relationships, healthy gross margins (60-75%), and some combination of subscription revenue and retail distribution. This is where most quality supplement businesses trade.
• Premium/high-growth DTC brands: 4-6x revenue. Strong brand with cult following, 70%+ gross margins, 30%+ subscription rate, expanding into retail with strong sell-through, and demonstrable growth trajectory. These attract strategic acquirers.

The variance within these tiers is driven by specific metrics that I'll break down below. But the headline insight is this: in supplements, brand is everything. Two businesses selling the same category of products (say, protein powder) at the same revenue can have wildly different valuations based on who is buying the product, how they found it, and whether they come back without being reminded.

Channel Mix: The Amazon Dependency Problem

This is the single most important factor in supplement brand valuation, and it's the one that crushes the most founders when they go to market. If more than 60% of your revenue comes from Amazon, your valuation will be materially lower than a comparable brand with diversified channels.

The reasons are well understood by acquirers. Amazon owns the customer relationship, not you. Amazon can change its algorithm, fee structure, or advertising costs at any time, and you have no recourse. Amazon can introduce a private-label competitor (Amazon Basics, Solimo) that undercuts you by 30%. And critically, your customer data on Amazon is limited — you don't have email addresses, you can't build a direct relationship, and your ability to drive repeat purchases is mediated entirely by Amazon's platform.

I've seen this play out painfully. A supplement brand doing $8M on Amazon with 20% EBITDA margins looks attractive until you realize that 70% of their sales come from two ASINs, their PPC spend has increased 40% year-over-year while conversion rates declined, and they have zero first-party customer data. That business might trade at 1.5-2x revenue. The same brand with 40% DTC (Shopify), 30% Amazon, and 30% retail (Whole Foods, Sprouts, GNC) could trade at 3-4x.

The ideal channel mix that buyers want to see is roughly 40-50% DTC (owned website), 20-30% Amazon, and 20-30% brick-and-mortar retail. That diversification tells a buyer that the brand has broad appeal, isn't dependent on any single channel, and has multiple growth vectors.

Subscription and Auto-Ship Metrics

Supplements are a natural subscription product — consumers take them daily and need to replenish regularly. The recurring revenue from subscription (auto-ship) programs is the most valuable revenue a supplement brand can generate, and buyers price it accordingly.

The metrics that matter:

• Subscription rate: What percentage of DTC revenue comes from active subscriptions? Above 30% is good, above 50% is exceptional. Below 15% suggests the product doesn't drive habitual use or the brand hasn't invested in retention.
• Subscription churn: Monthly churn below 8% is strong for supplements. Above 12%, and buyers will question whether the product delivers enough value to retain consumers. The best brands I've seen run 4-6% monthly churn.
• Customer LTV to CAC ratio: A 3:1 LTV/CAC or better signals a healthy unit economics engine. Below 2:1, the business is spending too much to acquire customers who don't stick around long enough to generate profit.
• Average order value and frequency: Supplements with $45-65 AOV on a 30-60 day replenishment cycle create predictable cash flow. Buyers model these cohorts forward and value the visibility they provide.

Gross Margins and the DTC Advantage

Supplement gross margins are one of the most attractive aspects of the category for acquirers. A well-formulated DTC supplement brand typically runs 60-75% gross margins — meaning a product that costs $8-12 to manufacture and fulfill sells for $35-50. That margin structure allows significant investment in customer acquisition while still generating strong contribution margins.

Wholesale and retail margins are lower (35-50%) because of distributor markups, retailer margins, and trade spend (promotional discounts, slotting fees, co-op advertising). But retail revenue is still valuable because it provides brand validation and customer acquisition at a cost that is often lower than digital advertising.

The margin story buyers want to see is a blended gross margin of 55%+ with a clear path to improvement. If your COGS have been creeping up due to ingredient costs or you're over-discounting to maintain Amazon ranking, address it before going to market. Every point of gross margin at $10M revenue is $100K of annual profit, which at a 3-4x revenue multiple translates to meaningful valuation impact.

FDA Compliance and Third-Party Certifications

Supplements are regulated by the FDA under DSHEA (Dietary Supplement Health and Education Act), and compliance is non-negotiable for any serious acquirer. The baseline requirement is that your manufacturing facility (or contract manufacturer) operates under cGMP (current Good Manufacturing Practices) as defined in 21 CFR Part 111.

Beyond the baseline, third-party certifications add tangible value:

• NSF International certification is the gold standard for supplement quality verification. NSF-certified products undergo regular facility audits, product testing, and label claim verification. Retailers like Whole Foods and Costco increasingly require NSF or equivalent certification.
• USP (United States Pharmacopeia) verification provides similar credibility, particularly for vitamins and minerals. A USP-verified product has been tested for identity, strength, purity, and dissolution.
• Informed Sport/Informed Choice certification is essential for brands targeting athletes, as it tests for banned substances. This certification opens the sports nutrition retail channel.
• Non-GMO Project, USDA Organic, and similar certifications add value for brands positioning in the natural/clean channel.

I've seen acquisitions stall or collapse during diligence because the target company couldn't produce adequate quality control documentation, had adverse event reports they hadn't properly filed, or was making structure/function claims that crossed the line into drug claims. Get your compliance house in order well before going to market.

Formulation IP and Brand Moat

Acquirers pay premium multiples for supplement brands with defensible intellectual property. This can take several forms:

Proprietary formulationsthat use patented ingredient forms (like branded forms of curcumin, magnesium chelates, or bioavailability-enhanced compounds) create a product that competitors can't easily replicate. If your hero product uses Curcugen, Albion minerals, or similar patented ingredients with exclusive supply agreements, that's a genuine moat.

Clinical studiesbacking your formulations are increasingly important. Brands that have invested in human clinical trials — even small pilot studies — demonstrating efficacy command premium valuations. The study doesn't need to be published in JAMA, but it needs to be legitimate, IRB-approved, and reproducible.

Brand recognition and community are harder to quantify but critically important. A supplement brand with 200K engaged Instagram followers, a podcast with loyal listeners, or a founder with genuine credibility in the wellness space has a consumer products asset that extends beyond the specific products. Buyers know they can launch new SKUs into that audience at a fraction of the cost of building awareness from scratch.

Who's Buying Supplement Brands

The acquirer landscape is a mix of strategic CPG companies, PE-backed platforms, and larger supplement businesses acquiring for category expansion.

Nestlé Health Science has been the most active strategic acquirer in the space, having acquired brands like Garden of Life, Nuun, Orgain, and Pure Encapsulations. They look for brands with $50M+ revenue, strong retail presence, and clinical credibility. Unilever has been active through its health and wellness portfolio. Church & Dwight (Vitafusion, L'il Critters) acquires in the vitamin and gummy space.

At the $5-30M revenue range, PE-backed platforms are the most likely buyers. Firms like Highlander Partners, TSG Consumer Partners, and Catterton have dedicated health and wellness teams that actively evaluate supplement acquisitions. These platforms typically acquire a "hero brand" as the anchor and then bolt on complementary brands to build a portfolio.

Amazon FBA aggregators (Thrasio, Perch, etc.) were active buyers in 2020-2022 but have largely pulled back after the aggregator correction. Some remain active in supplements, but they're more selective and paying lower multiples than the peak. If an Amazon-focused aggregator is your primary buyer, your ecommerce valuation will reflect the current reality of that market, not the 2021 euphoria.

The Bottom Line

Supplement brand valuations in 2026 are driven by channel diversification, subscription economics, gross margin quality, and brand defensibility. The businesses commanding 3-5x revenue are those with strong DTC channels, 30%+ subscription rates, third-party quality certifications, and a brand that means something to consumers beyond the product itself. The businesses struggling to trade at cost are Amazon-dependent, commodity-positioned, and undifferentiated. If you're building toward an exit, invest in the things that create a moat — proprietary formulations, clinical validation, direct customer relationships, and retail shelf presence — because those are the assets that acquirers pay multiples for.